Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine. (Q51811587)

13 April 2018

title

Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine. (English)

1 reference

13 April 2018

0 references

9

1 reference

13 April 2018

Gitte Moos Knudsen

11

1 reference

13 April 2018

Lars Hageman Pinborg

7

Lars H Pinborg

0 references

Jan Kalbitzer

6

Jan Kalbitzer

0 references

William F. C. Baaré

8

William F C Baaré

0 references

David Erritzøe

3

David Erritzoe

0 references

Birte Yding Glenthøj

12

Birte Glenthoj

0 references

Henrik Lublin

10

Henrik Lublin

0 references

Bjørn H Ebdrup

2

Bjorn H Ebdrup

1 reference

13 April 2018

Bodil Aggernæs

4

Bodil Aggernaes

1 reference

13 April 2018

Bob Oranje

5

Bob Oranje

1 reference

13 April 2018

author name string

Hans Rasmussen

1

1 reference

13 April 2018

publication date

8 July 2010

1 reference

13 April 2018

number of pages

10

0 references

published in

Psychopharmacology

1 reference

13 April 2018

volume

213

1 reference

13 April 2018

page(s)

583-592

1 reference

13 April 2018

issue

2-3

1 reference

13 April 2018

https://scigraph.springernature.com/pub.10.1007/s00213-010-1941-5

exact match

0 references

cites work

A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

Evidence for altered post-receptor modulation of the serotonin 2a receptor in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

Clinical pharmacokinetics of quetiapine: an atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

Reproducibility of 5-HT2A receptor measurements and sample size estimations with [18F]altanserin PET using a bolus/infusion approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

Consensus nomenclature for in vivo imaging of reversibly binding radioligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

When should clozapine be initiated in schizophrenia?: Some arguments for and against earlier use of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

Binding characteristics of the 5-HT2A receptor antagonists altanserin and MDL 100907.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

High-dose quetiapine in treatment refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

Quantification of 5-HT2A receptors in the human brain using [18F]altanserin-PET and the bolus/infusion approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

[18F]altanserin binding to human 5HT2A receptors is unaltered after citalopram and pindolol challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

[123I]epidepride binding to cerebellar dopamine D2/D3 receptors is displaceable: implications for the use of cerebellum as a reference region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

Decreased Frontal Serotonin2A Receptor Binding in Antipsychotic-Naive Patients With First-Episode Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

Quetiapine: dose-response relationship in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

MR-based automatic delineation of volumes of interest in human brain PET images using probability maps

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

A voxel-by-voxel analysis of [18F]setoperone PET data shows no substantial serotonin 5-HT(2A) receptor changes in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

SCAN. Schedules for Clinical Assessment in Neuropsychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

Quetiapine dosage in bipolar disorder episodes and mixed states

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-1941-5

Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade.

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Rapid Automated Algorithm for Aligning and Reslicing PET Images

1 reference

12 December 2020

Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 y

1 reference

12 December 2020

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

12 December 2020

The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice.

1 reference

12 December 2020

Transmitter dysfunction during the process of schizophrenia.

1 reference

12 December 2020

Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies.

1 reference

12 December 2020

High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study

1 reference

12 December 2020

Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography

1 reference

12 December 2020

Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent

1 reference

12 December 2020

10.1007/S00213-010-1941-5

Identifiers

DOI

1 reference

13 April 2018

PubMed ID

20614105

1 reference

13 April 2018